Last reviewed · How we verify
nasal naloxone
Naloxone is an opioid antagonist that blocks opioid receptors to rapidly reverse opioid overdose effects.
Naloxone is an opioid antagonist that blocks opioid receptors to rapidly reverse opioid overdose effects. Used for Opioid overdose reversal, Emergency treatment of known or suspected opioid overdose.
At a glance
| Generic name | nasal naloxone |
|---|---|
| Sponsor | Norwegian University of Science and Technology |
| Drug class | Opioid antagonist |
| Target | Opioid receptors (mu, delta, kappa) |
| Modality | Small molecule |
| Therapeutic area | Emergency medicine / Toxicology |
| Phase | FDA-approved |
Mechanism of action
Naloxone competitively binds to opioid receptors (mu, delta, and kappa) with higher affinity than opioids, displacing opioids from these receptors and reversing respiratory depression, sedation, and other opioid effects. The nasal formulation allows rapid intranasal absorption for quick onset of action in emergency overdose situations. This is particularly valuable for opioid overdose reversal in community and out-of-hospital settings.
Approved indications
- Opioid overdose reversal
- Emergency treatment of known or suspected opioid overdose
Common side effects
- Acute withdrawal syndrome (in opioid-dependent patients)
- Nasal irritation
- Headache
- Tachycardia
Key clinical trials
- Combination Gerotherapeutic Interventions for Healthspan Improvement (PHASE3)
- Neural Mechanisms of Immersive Virtual Reality in Chronic Pain (PHASE1, PHASE2)
- A Model to Save Lives Through a Volunteer First Responder Service Providing Antidote Treatment in Opioid Overdose (NA)
- The Role of the Opioid System in Placebo Effects on Pain and Social Rejection (EARLY_PHASE1)
- Novel Approach for the Prevention of Hypoglycemia Associated Autonomic Failure (HAAF) (PHASE4)
- Pharmacist-Led Interventions to Increase Access to Medications for Opioid Use Disorders (PLI-MOUD) (NA)
- Pharmacokinetics of Intravenous and Intranasal Formulations of Naloxone in Healthy Volunteers. (PHASE1)
- Pharmacodynamic Evaluation of Intranasal Nalmefene (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- nasal naloxone CI brief — competitive landscape report
- nasal naloxone updates RSS · CI watch RSS
- Norwegian University of Science and Technology portfolio CI